During the last session, C4 Therapeutics Inc (NASDAQ:CCCC)’s traded shares were 1.42 million, with the beta value of the company hitting 3.23. At the end of the trading day, the stock’s price was $6.24, reflecting an intraday loss of -3.55% or -$0.23. The 52-week high for the CCCC share is $11.88, that puts it down -90.38 from that peak though still a striking 83.01% gain since the share price plummeted to a 52-week low of $1.06. The company’s market capitalization is $428.06M, and the average trade volume was 2.59 million shares over the past three months.
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
C4 Therapeutics Inc (CCCC) registered a -3.55% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.55% in intraday trading to $6.24, hitting a weekly high. The stock’s 5-day price performance is -9.70%, and it has moved by -21.41% in 30 days. Based on these gigs, the overall price performance for the year is 104.59%.
C4 Therapeutics Inc (CCCC) estimates and forecasts
Statistics show that C4 Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. C4 Therapeutics Inc (CCCC) shares have gone up 342.55% during the last six months, with a year-to-date growth rate more than the industry average at 30.34% against 12.90. In the rating firms’ projections, revenue will increase 29.30% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 8.1M as predicted by 5 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 3.88M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 5.15M and 2.66M respectively. In this case, analysts expect current quarter sales to grow by 57.30% and then jump by 45.60% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -36.05%. While earnings are projected to return 30.76% in 2024, the next five years will return 22.30% per annum.
CCCC Dividends
C4 Therapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
